Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies
Giorgio Treglia, Luca Ceriani and Luca Giovanella
Affiliation: Department of Nuclear Medicine and PET/CT Center, Ente Ospedaliero Cantonale, via Ospedale, 12; zip code: 6500; Bellinzona, Switzerland.
Keywords: Dementia with Lewy bodies, dementia, innervation imaging, metaiodobenzylguanidine, MIBG.
Dementia with Lewy bodies (DLB) is the second most common cause of degenerative dementia after Alzheimer’s
disease (AD). To improve the diagnosis of DLB, the latest diagnostic criteria incorporate findings from neuroimaging
studies including sympathetic innervation imaging with iodine-123-metaiodobenzylguanidine (MIBG). According
to these criteria a decreased MIBG myocardial uptake is an important finding supporting a clinical diagnosis of DLB. In
this review the state of art and future perspectives of sympathetic innervation imaging by using MIBG in the diagnosis of
DLB are discussed.
Rights & PermissionsPrintExport